目的 觀察參附注射液聯(lián)合FOLFOX4方案治療直腸癌的臨床研究。方法 選取武警上海市總隊(duì)醫(yī)院2014年5月-2016年6月收治的直腸癌患者120例作為研究對(duì)象，采用隨機(jī)數(shù)字表法將患者分為對(duì)照組和治療組，每組各60例。對(duì)照組采用FOLFOX4方案治療；治療組在對(duì)照組的基礎(chǔ)上，靜脈滴注參附注射液，30～60 mL加入5%葡萄糖注射液250 mL，1次/d，連續(xù)10 d，最長20 d。從治療開始，兩組均觀察1個(gè)月。觀察兩組的臨床療效，比較兩組生活質(zhì)量評(píng)分、營養(yǎng)指標(biāo)、血清免疫指標(biāo)和毒副作用。結(jié)果 治療后，對(duì)照組、治療組疾病控制率分別為88.33%、95.00%，兩組疾病控制率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對(duì)照組、治療組卡氏（KPS）評(píng)分提高率分別為41.67%、58.33%，兩組KPS評(píng)分提高率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者白蛋白（ALB）、前白蛋白（PA）、總蛋白（TP）、轉(zhuǎn)鐵蛋白（TF）水平以及IgG、IgA、IgM水平和總淋巴細(xì)胞計(jì)數(shù)（TLC）均明顯降低，與同組治療前比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)比對(duì)照組降低得更明顯（P<0.05）。治療組不良反應(yīng)發(fā)生率均低于對(duì)照組，兩組不良反應(yīng)發(fā)生率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 參附注射液聯(lián)合FOLFOX4方案治療直腸癌療效顯著，可明顯改善臨床療效，提高患者生活質(zhì)量，改善營養(yǎng)指標(biāo)和血清免疫指標(biāo)，減輕毒副作用，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical curative effect of Shenfu Injection combined with FOLFOX4 regimen in treatment of rectal cancer. Methods Patients (120 cases) with rectal cancer in Shanghai Armed Police Corps Hospital from May 2014 to June 2016 were enrolled in this study. According to the random number table, patients were divided into the control group and treatment group, and each group had 60 cases. Patients in the control group were treated with FOLFOX4 regimen. Patients in the treatment group were iv administered with Shenfu Injection on the basis of the control group, 30-60 mL added into 5% glucose Injection 250 mL, once daily, lasted for 10-20 d. Patients in two groups were observed for one month. After treatment, the efficacy was evaluated, and quality of life, nutritional indexes, serum immune indexes, and adverse reactions in two groups were compared. Results After treatment, disease control rates in the control and treatment groups were 88.33% and 95.00%, respectively, and there were differences between two groups (P<0.05). Improvement rates of KPS score in the control and treatment groups were 41.67% and 58.33%, respectively, and there were differences between two groups (P<0.05). After treatment, levels of ALB, PA, TP, TF, IgG, IgA, IgM, and TLC in two groups were significantly decreased (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group (P<0.05). Compared with the control group, adverse reaction rates in the treatment group were lower than those in the treatment group, with significant difference between two groups (P<0.05). Conclusion Shenfu Injection combined with FOLFOX4 regimen have clinical curative effect in treatment of rectal cancer, can obviously improve the clinical symptoms, improve the quality of life, improve nutritional index and serum immune index, reduce adverse reactions, which has a certain clinical application value.